Revaprazan Hydrochloride CAS 178307-42-1 Assay ≥99.0% API Factory High Purity

Short Description:

Name: Revaprazan Hydrochloride; Revaprazan HCL

CAS: 178307-42-1

Appearance: White or Off-White Crystalline Powder

Assay: ≥99.0%

Potassium-competitive acid blockers (P-CAB), in the treatment of duodenal ulcer, gastric ulcer and gastritis

API High Quality, Commercial Production

E-mail: alvin@ruifuchem.com

Send email to us

Product Detail

Product Tags

Description:

Chemical Name: Revaprazan Hydrochloride; Revaprazan HCL
CAS: 178307-42-1
API High Quality, Commercial Production

Chemical Properties:

Chemical Name	Revaprazan Hydrochloride
Synonyms	Revaprazan HCL
CAS Number	178307-42-1
CAT Number	RF-API48
Stock Status	In Stock, Production Scale Up to Hundreds of Kilograms
Molecular Formula	C22H24ClFN4
Molecular Weight	398.904
Brand	Ruifu Chemical

Specifications:

Item	Specifications
Appearance	White or Off-White Crystalline Powder
Solubility	Freely soluble in chloroform, dichlormeth; Soluble in Acetic acid; Slightly soluble in methanol, DMSO; Hardly soluble in acetone, ACN; Almost not soluble in 0.1mol/L NaOH solution. 0.1mol/L HCL solution.
Identification	Should be positively responded λ max 271nm 、205nm IR
Melting Point	219.0~222.0℃
Clarity and Color	Should be clear and colorless in dichlormeth
Chloride	≤8.93%
Single Impurity	≤0.10%
Total Impurities	≤0.50%
Loss on Drying	≤0.50%
Residue on Ignition	≤0.10%
Sulfate	≤20ppm
Arsenic	≤10ppm
Heavy Metals	≤10ppm
Assay	≥99.0%
Test Standard	Enterprise Standard
Usage	Active Pharmaceutical Ingredient (API)

Package & Storage:

Package: Bottle, Aluminum foil bag, Cardboard drum, 25kg/Drum, or according to customer's requirement.

Storage Condition: Store in sealed containers at cool and dry place; Protect from light, moisture and pest infestation.

Advantages:

FAQ:

Application:

Shanghai Ruifu Chemical Co., Ltd. is the leading manufacturer and supplier of Revaprazan Hydrochloride (CAS: 178307-42-1) with high quality. Revaprazan Hydrochloride reduces COX-2 expression and has significant anti-inflammatory actions activities in H. pylori infection. Revaprazan Hydrochloride in the treatment of duodenal ulcer, gastric ulcer and gastritis.
Revaprazan Hydrochloride (also known as reversible proton pump inhibitors, potassium competitive acid blockers, p-CABs) is a new generation of reversible proton pump inhibitors and the only commercially available potassium competitive acid pump inhibitors or acid pump antagonists in the world. Developed by South Korean company Yuhan and with proprietary intellectual property rights, GLAxoSmithKline has obtained worldwide development and marketing licenses for the drug outside of South Korea and North Korea. The drug was approved by the South Korean FDA in 2007 to treat duodenal ulcers and gastritis.